AMPH vs PFE: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
PFE is the larger of the two ($156.92B market cap): the incumbent the market prices for continued execution (9.32x forward earnings, beta 0.30). AMPH is the smaller challenger ($1.20B), priced similarly on forward earnings (8.41x): more room to run, but more to prove. AMPH is expected to grow revenue faster (4% vs -4% next year) at a similar price (8.41x vs 9.32x forward earnings). The case for PFE rests on its own driver (Oncology expansion via Seagen): if you believe in that, PFE fits; if you believe in what the numbers show today, AMPH does.
AMPH vs PFE: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | AMPH | PFE | What it tells you |
|---|---|---|---|
| Market cap | $1.20B | $156.92B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 8.41 | 9.32 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 12.93 | 39.33 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.94 | 0.30 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 80% of range | 50% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.48 | 1.76 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how AMPH and PFE affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AMPH and PFE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AMPH and PFE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Amphastar Pharmaceuticals (AMPH) do?
Amphastar Pharmaceuticals (Nasdaq: AMPH), based in Rancho Cucamonga, California, develops, manufactures and sells technically difficult generic and proprietary injectable, inhalation and intranasal medicines. It makes more than 30 products, and its own active pharmaceutical ingredients (including insulin API) through a subsidiary in China. The largest sellers are BAQSIMI, the nasal glucagon rescue spray bought from Eli Lilly in 2023, the over-the-counter asthma inhaler Primatene MIST, and hospital staples such as epinephrine, lidocaine and glucagon kits. Most volume flows through group purchasing organizations, wholesalers and retailers.
What does Pfizer (PFE) do?
Pfizer is one of the world's largest pharmaceutical companies, developing, manufacturing, and selling prescription medicines and vaccines across many therapeutic areas. Its portfolio spans oncology (a strategic priority, expanded sharply by the acquisition of cancer drugmaker Seagen), vaccines (including pneumococcal franchise Prevnar and its COVID-19 vaccine Comirnaty, partnered with BioNTech), internal medicine and cardiology (such as the Vyndaqel/Vyndamax family and Eliquis, co-marketed with Bristol Myers Squibb), immunology and inflammation, and antivirals (including the COVID treatment Paxlovid). Pfizer makes money selling these drugs to wholesalers, pharmacies, hospitals, and governments worldwide. The company saw an enormous revenue surge from COVID-19 products during the pandemic, then a steep decline as that demand normalized, leaving it to refill growth through its pipeline, oncology expansion, and acquisitions while a wave of patent expirations looms later this decade. Founded in 1849 and headquartered in New York City, Pfizer is a mature, dividend-paying large-cap navigating a post-COVID reset.
AMPH vs PFE: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- AMPH drivers: BAQSIMI volume versus net price; New generic and inhalation launches.
- PFE drivers: Oncology expansion via Seagen; Broad, diversified portfolio.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Legacy erosion is the most visible risk: glucagon kit sales fell ~37% in Q3 2026 on competition, and epinephrine fell ~19% as releases from the IMS plant slowed. For PFE, pfizer faces a significant patent cliff later this decade, with several major products losing exclusivity, pressuring revenue unless the pipeline and acquisitions fill the gap.
AMPH or PFE: which should you pick?
If the story you believe is AMPH's (BAQSIMI volume versus net price), AMPH is the more direct way to own it; if it is PFE's (Oncology expansion via Seagen), PFE is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AMPH and PFE guides.
AMPH vs PFE: the full fundamentals
AMPH. Priced at the $28.15 close on November 20, 2026, Amphastar trades near 13x trailing GAAP earnings, 8.4x forward estimates and about 8.4x EV/EBITDA. The gap between GAAP and adjusted earnings comes mainly from amortization of the BAQSIMI intangible and share-based compensation. Net debt is roughly ~$460 million, and the six analysts in the consensus rate the stock Hold on average with a mean target of ~$24.50, below the current price.
PFE. At about $27.54 (November 20, 2026) Pfizer trades at about 9x forward earnings with a dividend yield near 6.3%, a below-market multiple that reflects investor concern about the post-COVID revenue reset and a looming patent cliff. The gap between a trailing GAAP P/E near 39x and the forward figure comes from large GAAP charges, including a GAAP loss in Q2 2026, rather than weak operations. After pulling back from its early-November high the stock sits below the 26 analysts' mean target of about $30.22 (an average buy rating), so the valuation balances substantial cash generation against flat-to-lower consensus earnings.
Headline figures (approximate, November 2026): AMPH shows revenue (ttm) ~$746 million, revenue growth (q3 2026, yoy) ~8%, gaap net income (ttm) ~$99 million, q3 2026 adjusted eps $1.14 (vs ~$0.86 expected); PFE shows revenue (ttm) ~$63.6 billion (Q3 2026 ~flat YoY), operating margin ~29%, net income (ttm, gaap) ~$4.0 billion, q3 2026 adjusted eps ~$0.87 vs ~$0.74 consensus.
The bottom line: AMPH vs PFE
AMPH and PFE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined AMPH and PFE exposure against your real portfolio. It is not an investment adviser.
Wondering how AMPH or PFE fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Amphastar Pharmaceuticals
Ask Walnut's AI anything about AMPH and see how it fits what you own.
FAQ
What is the difference between AMPH and PFE?
+
Amphastar Pharmaceuticals (Nasdaq: AMPH), based in Rancho Cucamonga, California, develops, manufactures and sells technically difficult generic and proprietary injectable, inhalation and intranasal medicines. Pfizer is one of the world's largest pharmaceutical companies, developing, manufacturing, and selling prescription medicines and vaccines across many therapeutic areas. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is AMPH or PFE the better stock?
+
Neither is universally better. PFE is the larger incumbent; AMPH is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, AMPH or PFE?
+
On forward P/E (as of November 2026), AMPH trades at 8.41x and PFE at 9.32x, so AMPH is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both AMPH and PFE?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of AMPH vs PFE?
+
AMPH: Legacy erosion is the most visible risk: glucagon kit sales fell ~37% in Q3 2026 on competition, and epinephrine fell ~19% as releases from the IMS plant slowed. BAQSIMI net pricing is under pressure from rebates, 340B discounts and payer mix, so prescription growth does not translate one-for-one into revenue. Regulatory risk rose in July 2026 when the FDA issued a warning letter to the IMS plant in South El Monte, California, citing cGMP problems in investigations, environmental monitoring and equipment; production continues, but remediation cost about $2-3 million in Q3, management expects somewhat higher costs for the next two or three quarters, backorders stood at ~$12.5 million, and the FDA can take further action. Pipeline timing is uncertain, since insulin aspart already passed an earlier Q1 2026 goal date without approval and two other filings slipped into the second half of 2027. The balance sheet carries ~$692 million of debt against ~$231 million of cash. Two founders and executives have pledged shares as loan collateral, and a forced sale by a lender could pressure the stock; insiders also sold about $1.1 million of shares in November 2026 filings. Tariffs, drug pricing reform and Chinese API exposure add policy risk, and the stock trades above the average analyst target after a ~28% three-month rally. PFE: Pfizer faces a significant patent cliff later this decade, with several major products losing exclusivity, pressuring revenue unless the pipeline and acquisitions fill the gap. Analysts' consensus as of November 2026 has revenue of about $63.1 billion in 2026 slipping to $60.8 billion in 2027, with EPS of roughly $3.05 and $2.95, so earnings are expected to drift lower rather than grow. COVID-19 product revenue (Comirnaty, Paxlovid) has fallen sharply and remains volatile and hard to forecast. The Seagen deal added substantial debt (total debt is about $63.4 billion against $14.3 billion of cash), and large acquisitions carry integration and return risk. The dividend exceeds GAAP earnings (a payout near 246% of trailing GAAP EPS of about $0.70), so it leans on adjusted earnings and cash flow. Drug pricing pressure, including US policy such as Medicare negotiation, threatens margins on key products. Pipeline setbacks, clinical-trial failures, and regulatory decisions can swing the stock, and the company must continually prove it can generate new blockbusters to sustain growth as legacy drugs mature.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AMPH or PFE; figures are approximate and dated (as of November 2026). Verify current data before investing.